Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs (Endpoints)
Fulcrum's Phase 3 for old GSK drug fails, stock sinks (Endpoints)
GSK’s mRNA flu shot is heading to Phase 3; Summit’s $235M offering (Endpoints)
Charles River to lay off 3% of staffers as it streamlines spending (Endpoints)
A new startup wants to fight cancer with 'off-the-shelf' gene therapy, securing $26M seed round (Endpoints)
Medtech
Roche to launch new CGM in Europe in ‘coming weeks’ (MedTech Dive)
SS Innovations expects US OK for surgical robot in 2025 (MedTech Dive)
FDA to investigate presence of metals in tampons (MedTech Dive)
J&J leads $50M financing for imaging company Spectrawave (MedTech Dive)
Dexcom, Abbott OTC glucose sensors add to busy year for diabetes tech (MedTech Dive)
Government, Regulatory & Legal
5 takeaways from Congress’ hearing on overhauling organ transplant system (STAT)
Update on the DEA's efforts to reschedule cannabis: what you need to know (Reuters)
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
The US Food and Drug Administration (FDA) has issued draft guidance to assist sponsors in developing early-phase first-in-human (FIH) studies for investigational drugs and biologics aimed at treating solid tumors as part of Operation TrialBlazer.